Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia

Neuropsychopharmacology

Volumn 27, Issue 6, 2002, Pages 1050-1055

  Fabrazzo, Michele ^a   La Pia, Silvestro ^b   Monteleone, Palmiero ^a   Esposito, Giuseppina ^a   Pinto, Antonio ^b   De Simone, Luigi ^b   Bencivenga, Rachele ^a   Maj, Mario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Department of Mental Health   (Italy)

Author keywords

Clinical response; Clozapine; Plasma levels; Schizophrenia

Indexed keywords

CLOZAPINE; DRUG METABOLITE;

ADULT; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG RESISTANCE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TIME;

ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; CLOZAPINE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TIME FACTORS;

EID: 0036898975     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00319-6     Document Type: Article

References (30)

1. Bender S., Eap C.B. Very high cytocrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry. 55:1998;1048-1050.
2. Bergling R., Mjorndal T., Orendal L., Rapp W., Wold S. Plasma levels and clinical effect of thioridazine and thiothixene. J Clin Pharmacol. 15:1975;178-186.
3. Centorrino F., Baldessarini R.J., Kando J.C., Frankenburg F.R., Volpicelli S.A., Flood J.G. concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol. 14:1994;119-125. a.
4. Centorrino F., Baldessarini R.J., Kando J.C., Frankenburg F.R., Volpicelli S.A., Puopolo P.R., Flood J.G. effects of cotreatment with valproate or fluoxetine. Am J Psychiatry. 151:1994;123-126. b.
5. Conley R.R., Carpenter Wt J.R., Tamminga C.A. Time to clozapine response in a standardized trial. Am J Psychiatry. 154:1997;1243-1247.
6. Fabrazzo M., Esposito G., Fusco R., Maj M. Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women. Psychopharmacology (Berl). 124:1996;197-200.
7. Fabrazzo M., La Pia S., Monteleone P., Mennella R., Esposito G., Pinto A., Maj M. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time-and dose-dependent manner. J Clin Psychopharmacol. 20:2000;708-710.
8. Fitton A., Heel R.C. Clozapine. a review of its pharmacological properties, and therapeutic use in schizophrenia Drugs. 40:1990;722-747.
9. Hasegawa M., Gutierrez-Esteinon R., Way L., Meltzer H.Y. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia. effect of smoking J Clin Psychopharmacol. 13:1993;383-390.
10. Jann M.W., Grimsley S.R., Gray E.C., Chang W.-H. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet. 24:1993;161-176.
11. Jann M.W., Lan Y.W.F., Chang W.-H. Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration. Arch Int Pharmacod. 328:1994;243-250.
12. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. a double-blind comparison with chlorpromazine Arch Gen Psychiatry. 45:1988;789-796.
13. Korpi E.R., Costakos D.T., Wyart R.J. Rapid formation of reduced haloperidol in guinea pigs following haloperidol administration. Acta Pharmacol Toxicol. 56:1985;94-98.
14. Kronig M.H., Munne R.A., Szymanski S., Safferman A.Z., Pollack S., Cooper T., Kane J.M., Lieberman J.A. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 152:1995;179-182.
15. Kurz M., Hummer M., Kemmler G., Kurzthaler I., Saria A., Fleischhacker W.W. Long-term pharmacokinetics of clozapine. Br J Psychiatry. 173:1998;341-344.
16. Lieberman J.A., Safferman A.Z., Pollack S. Clinical effects of clozapine in chronic schizophrenia. response to treatment and predictors of outcome Am J Psychiatry. 151:1994;1744-1752.
17. Lin S.K., Chang W.-H., Chung M.C., Lan Y.W.F., Jann M.W. Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol. 34:1994;318-324.
18. Lukoff D., Nuechterlein K.H., Ventura J. Manual for Expanded Brief Psychiatric Rating Scale (BPRS). Schizophrenia Bull. 12:1986;594-602.
19. Meltzer H.Y. Dimensions of outcome with clozapine. Br J Psychiatry. 160:1992;46-53.
20. Meltzer H.Y., Bastani B., Kwon K.Y., Ramirez L.F., Burnett S., Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients, I. preliminary report Psychopharmacology (Berl). 99:1989;568-572.
21. Meltzer H.Y., Burnett S., Bastani B., Ramirez L.F. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry. 41:1990;892-897.
22. Miller D.D., Fleming F., Holman T.L., Jerry P.J. Plasma clozapine concentrations as a predictor of clinical response. a follow-up study J Clin Psychiatry. 55:1994;117-121.
23. Perry P.J., Miller D.D., Arndt S.V., Cadoret R.J. Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenics patients. Am J Psychiatry. 148:1991;231-236.
24. Pickar D., Owen R.R., Litman R.E., Konicki P.E., Guitierrez R., Rapaport M.H. Clinical and biological response to clozapine in patients with schizophrenia. Arch Gen Psychiatry. 43:1992;345-353.
25. Potkin S.G., Bera R., Gulasekaram B., Costa J., Hayes S., Jin Y., Richmond G., Carreon D., Sitanggan K., Gerber B., Telford J., Plon L., Plon H., Park L., Chang Y.J., Oldroyd J., Cooper T.B. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 55:1994;133-136.
26. Sakalis G., Chan T.L., Gershon S., Park S. The possible role of metabolites in therapeutic response to chlorpromazine treatment. Psychopharmacologia. 32:1973;279-284.
27. Stern R.G., Kahn R.S., Davidson M., Nora R.M., Davis K.L. Early response to clozapine in schizophrenia. Am J Psychiatry. 151:1994;1817-1818.
28. VanderZwaag C., McGee M., McEvoy J.P., Freudenreich O., Wilson W.H., Cooper T.H. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry. 153:1996;1579-1584.
29. Volpicelli S.A., Centorrino F., Puopolo P.R., Kando J.C., Frankenburg F.R., Baldessarini R.J., Flood J.G. Determination of clozapine, norclozapine and clozapine-N-oxide in serum by liquid chromatography. Clin Chem. 39:1993;1656-1659.
30. Wilson W.H. Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am J Psychiatry. 153:1996;951-952.